Aethlon Medical (AEMD) Stock Price, News & Analysis

Company Overview

Aethlon Medical, Inc. is a clinical-stage medical device company focused on developing therapeutic technologies for cancer and life-threatening viral infections. The company’s lead product is the Hemopurifier, an investigational extracorporeal blood filtration device designed to selectively remove certain disease-causing particles, including tumor-derived exosomes and viruses, from the bloodstream.

The Hemopurifier is being evaluated as a potential adjunct to existing treatments. In oncology, the technology is intended to remove exosomes that may contribute to tumor progression and immune suppression. In infectious disease applications, it is designed to capture certain viral particles and may support the treatment of severe infections. The device remains investigational and is not approved for general commercial use in the United States.

Based in San Diego, California, Aethlon Medical has historically focused its research and development activities on the use of extracorporeal technologies in oncology and infectious disease. The company’s leadership has included Chairman and Chief Executive Officer Charles E. Fisher Jr., M.D.

Key Stats

• Today's Range: $6.27 to $6.66
• 50-Day Range: $1.43 to $6.81
• 52-Week Range: $1.41 to $41.35
• Volume: 118,463 shs
• Average Volume: 4.95 million shs
• Market Capitalization: $4.64 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.50
• Consensus Rating: Reduce

Aethlon Medical Stock Analysis - MarketRank™

Aethlon Medical scored higher than 28% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.2 / 5
• Analyst Rating: Reduce

Consensus Rating

Aethlon Medical has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.

Downside Risk

Aethlon Medical has a consensus price target of $1.50, representing about 77.0% downside from its current price of $6.52.

Amount of Analyst Coverage

Aethlon Medical has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Aethlon Medical are expected to grow in the coming year, from ($5.74) to ($0.57) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Aethlon Medical is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aethlon Medical is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Aethlon Medical has a P/B Ratio of 0.42. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

10.59% of the float of Aethlon Medical has been sold short.

Short Interest Ratio / Days to Cover

Aethlon Medical has a short interest ratio ("days to cover") of 0.41, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aethlon Medical has recently decreased by 83.79%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aethlon Medical does not currently pay a dividend.

Dividend Growth

Aethlon Medical does not have a long track record of dividend growth.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 1.15

News Sentiment

Aethlon Medical has a news sentiment score of 1.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Aethlon Medical this week, compared to 3 articles on an average week.

Search Interest

Only 8 people have searched for AEMD on MarketBeat in the last 30 days. This is a decrease of -11% compared to the previous 30 days.

MarketBeat Follows

1 people have added Aethlon Medical to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Aethlon Medical insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.60% of the stock of Aethlon Medical is held by insiders.

Percentage Held by Institutions

1.99% of the stock of Aethlon Medical is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/01/2026
• AGM 2026: 10/01/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:AEMD
• CIK: 882291
• Web: www.aethlonmedical.com
• Phone: (619) 941-0360
• Fax: N/A
• Employees: 9
• Year Founded: 1998

Price Target and Rating

• Average Price Target for Aethlon Medical: $1.50
• High Price Target: $1.50
• Low Price Target: $1.50
• Potential Upside/Downside: -77.0%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($34.97)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.15 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -123.08%
• Return on Assets: -99.28%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.42
• Quick Ratio: 5.42

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $15.56 per share
• Price / Book: 0.42

Miscellaneous

• Outstanding Shares: 711,000
• Free Float: 707,000
• Market Cap: $4.64 million
• Optionable: No Data
• Beta: 1.40